|
|
Volumn 16 Suppl 2, Issue , 2011, Pages 32-44
|
|
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BENZENESULFONIC ACID DERIVATIVE;
BEVACIZUMAB;
DRUG DERIVATIVE;
EVEROLIMUS;
INDOLE DERIVATIVE;
MONOCLONAL ANTIBODY;
MTOR PROTEIN, HUMAN;
PYRIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
RAPAMYCIN;
SORAFENIB;
SUNITINIB;
TARGET OF RAPAMYCIN KINASE;
TEMSIROLIMUS;
VASCULOTROPIN A;
VEGFA PROTEIN, HUMAN;
DRUG ANTAGONISM;
HUMAN;
IMMUNOTHERAPY;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PHASE 3 CLINICAL TRIAL (TOPIC);
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
IMMUNOTHERAPY;
INDOLES;
KIDNEY NEOPLASMS;
MOLECULAR TARGETED THERAPY;
PYRIDINES;
PYRROLES;
SIROLIMUS;
TOR SERINE-THREONINE KINASES;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 79955804850
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2011-S2-32 Document Type: Review |
|
Times cited : (76)
|
|
References (0)
|
